Search
Searching Content by Antony David from Khurana and Khurana ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
Federal Circuit Holds That Claims Directed To A Specific Method Of Treatment For Specific Patients Using A Specific Compound At Specific Doses To Achieve A Specific Outcome Satisfy 35 U.S.C. §101
On March 28, 2019, the Court of Appeals for the Federal Circuit (CAFC) issued an opinion in Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., reversing a decision by the United States
United States
6 May 2019
2
Federal Circuit Affirms Patent-Ineligibility Of Diagnostic Method Claims
On April 1, 2019, the Court of Appeals for the Federal Circuit (CAFC) issued a decision in Cleveland Clinic Foundation v. True Health Diagnostics LLC
India
1 May 2019
3
U.S. Jury Upheld Validity Of Two Patents For Amgen Inc's Cholesterol-Lowering Drug Repatha® (Evolocumab)
US healthcare giant Amgen has successfully defended two of its patents related to cholesterol-lowering drug Repatha® (evolocumab).
United States
1 Apr 2019
4
United States District Court For The District Of New Jersey Invalidates All Asserted Claims Of US Patent No. 8822438 For Prostate Cancer Drug Zytiga (Abiraterone Acetate)
US healthcare giant Johnson & Johnson on Oct. 26, 2018 announced that the District Court of New Jersey has issued a ruling that invalidates all the claims of J&J subsidiary Janssen's US Patent No. 8,822,438 for the prostate cancer drug Zytiga®.
India
30 Nov 2018
5
Federal Circuit Rules 180-Day Post-Licensure Notice Is Mandatory In Biosimilar Litigation
If the parties reach agreement, then the reference product sponsor must bring an infringement action within 30 days for each patent on the negotiated list.
India
27 Sep 2016
Links to Result pages
 
1